Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
News|Webinars|January 25, 2022
Optimizing the Payer/Provider Relationship for a Successful Annual Enrollment Period, Part 8
Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.
Advertisement
In the latest Matters in Managed Care webinar, experts discussed current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries. They discussed the health system, provider, and payer perspectives.
Steve Evans, MD, vice president for quality and utilization management, Intermountain Healthcare, moderated the panel with:
- Judith Ford, MD, medical director, Intermountain Healthcare
- Othella Ann Jurani-Suarez, MD, medical director, Intermountain Healthcare
- Kristine Gates, government program sales director, SelectHealth
- Matt Maher, senior sales manager, Humana
- Sherry Stanislaw, general manager, officer, SCAN Health Plan
In segment 8, they answer questions from the attendees.
Advertisement
Related to this article
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5